Biotech Values

[DewDiligence]

NVS’ Onbrez Breezhaler (f/k/a QVA149) non-inferior to GSK’s Advair (Seretide) in phase-4 study:

http://in.reuters.com/article/2014/04/25/us-novartis-lung-idINBREA3O0D920140425

Given the mega-deal between NVS and GSK announced this week, it’s a little strange that NVS and GSK are still competitors in the respiratory arena. One would think the companies discussed having NVS include its respiratory portfolio in the asset swap with GSK, who is the clear leader in this arena.